- Home
- MYNZ vs INDP Comparison
MYNZ vs INDP Comparison
Compare MYNZ & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- INDP
- Stock Information
- Founded
- MYNZ 2021
- INDP 2000
- Country
- MYNZ Germany
- INDP United States
- Employees
- MYNZ N/A
- INDP N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- INDP Health Care
- Exchange
- MYNZ Nasdaq
- INDP Nasdaq
- Market Cap
- MYNZ 5.5M
- INDP 5.0M
- IPO Year
- MYNZ 2021
- INDP N/A
- Fundamental
- Price
- MYNZ $1.37
- INDP $11.12
- Analyst Decision
- MYNZ Buy
- INDP Strong Buy
- Analyst Count
- MYNZ 2
- INDP 2
- Target Price
- MYNZ $14.00
- INDP $8.50
- AVG Volume (30 Days)
- MYNZ 118.7K
- INDP 689.8K
- Earning Date
- MYNZ 07-07-2025
- INDP 08-11-2025
- Dividend Yield
- MYNZ N/A
- INDP N/A
- EPS Growth
- MYNZ N/A
- INDP N/A
- EPS
- MYNZ N/A
- INDP N/A
- Revenue
- MYNZ $893,991.00
- INDP N/A
- Revenue This Year
- MYNZ $26.06
- INDP N/A
- Revenue Next Year
- MYNZ $4.97
- INDP N/A
- P/E Ratio
- MYNZ N/A
- INDP N/A
- Revenue Growth
- MYNZ N/A
- INDP N/A
- 52 Week Low
- MYNZ $1.34
- INDP $7.56
- 52 Week High
- MYNZ $22.40
- INDP $67.48
- Technical
- Relative Strength Index (RSI)
- MYNZ 23.25
- INDP 98.13
- Support Level
- MYNZ $1.34
- INDP $0.31
- Resistance Level
- MYNZ $1.48
- INDP $0.71
- Average True Range (ATR)
- MYNZ 0.13
- INDP 0.07
- MACD
- MYNZ -0.01
- INDP 0.77
- Stochastic Oscillator
- MYNZ 3.72
- INDP 99.09
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.